FindTrial
Sign In

Efficacy and Safety of Tranexamic Acid in Thoracolumbar Fracture-dislocation combined with neurological deficits

Efficacy and Safety of Tranexamic Acid in Thoracolumbar Fracture-dislocation combined with neurological deficits

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004378
Enrollment
Unknown
Registered
2014-03-14
Start date
2014-03-17
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracolumbar Fracture-dislocation

Interventions

Tranexamic Acid:Giving 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid.
Control:0.9% NS

Sponsors

Honghui Hospital Affiliated to Xi'an Jiaotong University/xi'an Honghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) fracture-dislocation (type C according to the Margel classification, type C means anteriormiddle and posterior column structure rotationally damage) of the thoracolumbar junction (T11–L2); (2) With neurological deficits; (3) Aged 20 to 60 years; (4) <24hours from the time of injury; (5) Only 2 vertebral bodies fracture-dislocation.

Exclusion criteria

Exclusion criteria: (1) fracture-dislocation above T11or below L2; (2) pathological or severe osteoporotic fractures; (3) incomplete radiological or clinical follow-up; (4) With fatal injury cant tolerate surgery such as severe craniocerebral injury/Abdominal/chest internal bleeding; (5) With hemopathy or high risk for thrombus.

Design outcomes

Primary

MeasureTime frame
molecular marker of prothrombotic state;—

Countries

China

Contacts

Public ContactWang Wentao

Honghui Hospital Affiliated to Xi'an Jiaotong University/xi'anHonghui Hospital

731624568@qq.com+86 13572571402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026